Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy vs Radiotherapy + Chemotherapy + Rituximab for Stage I-II Low Grade Follicular Lymphoma
NCT00115700Phase 3Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Feb 2000
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies, Lipid-based Nanoparticles, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, vincristine sulfate liposome injection and prednisolone in follicular lymphoma (FL) (2 arms), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoint: Progression Free Survival at 10 years. Started Feb 2000; status: completed.
02
Drugs
rituximabcyclophosphamidevincristine sulfate liposome injectionprednisolone
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00115700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115700.